Myocet Liposomal (Doxorubicin Hydrochloride)

Doxorubicin intercalates into DNA, inhibiting topoisomerase II and preventing the resealing of DNA strands during replication. This creates double‑strand breaks and triggers oxidative stress through free‑radical generation, leading to apoptosis of rapidly dividing cancer cells. The liposomal carrier helps concentrate the drug in tumour tissue.

The prescribed dose of Myocet Liposomal is determined by the treating physician based on factors such as the patient’s body surface area, disease stage, prior therapies, organ function and overall clinical condition. Dosing is individualized and adjusted according to response and tolerability.

Safety data for Myocet Liposomal in pregnancy and lactation are limited, and the drug may cause fetal harm. It is generally contraindicated during pregnancy and breastfeeding unless the potential benefit justifies the risk. Women of child‑bearing potential should use effective contraception during treatment.

To order Myocet Liposomal, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Myocet Liposomal encapsulates doxorubicin in liposomes, which can reduce exposure of healthy tissues and lower the incidence of certain side effects, especially cardiotoxicity, compared with conventional free‑form doxorubicin. Efficacy in approved indications is comparable, while the liposomal formulation may offer a more favourable safety profile for some patients.

Myocet Liposomal must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the product. Do not store at room temperature for prolonged periods, as stability may be compromised.

Myocet Liposomal is given as an intravenous infusion by a qualified healthcare professional. The infusion rate and duration are determined by the prescribing physician and may be adjusted based on patient tolerance and clinical response. It is typically administered in a clinical setting with appropriate monitoring.

The most serious risks include cardiotoxicity (which can lead to heart failure), severe neutropenia or febrile neutropenia, secondary acute myeloid leukemia, and severe infusion‑related reactions such as hypotension or bronchospasm. Regular cardiac and hematologic monitoring is essential to detect these complications early.

Myocet Liposomal should be avoided in patients with known hypersensitivity to doxorubicin or any liposomal components, those with uncontrolled cardiac disease, severe hepatic impairment, or active infections that could be worsened by immunosuppression. It is also contraindicated during pregnancy and lactation unless the benefits clearly outweigh the risks.